---

Dr. Brian Atkinson has over 20 years of experience as a researcher and medical writer. Prior to joining MedVal, Brian was the Lead Medical Writer for the Immunoscience and CNS franchises at Bristol-Myers Squibb, where he worked on priority presentations and publications in transplant immunosuppression (Nulogix), rheumatoid arthritis (Orencia), psoriatic arthritis (clazakizumab) and acute migraine therapy (CGRP antagonist). Brian’s work as the principal writer for Nulogix resulted in 12 published manuscripts and 19 oral presentations at scientific and medical congresses. Brian also lead an initiative that provided training in Good Publication Practices to over 200 staff members from over 30 overseas markets.

Prior to working at Bristol-Myers, Brian worked for eight years as a senior medical writer and medical director at PharmaWrite, where he developed over 25 priority presentations and publications in preparation for the launch of Topamax in migraine prevention. In addition, Brian wrote or oversaw development of publications relating to neuropathic pain (Ultracet, Topamax) and psychiatric disorders such as binge eating and bulimia nervosa (Topamax), and participated in advisory boards for addiction treatment (Prometa). Brian also worked as the lead writer on a series of stand-alone European continuing medical education conferences that annually drew over 300 rheumatologists and dermatologists to state of the art presentations on rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Brian received his doctorate in Pharmacology from Emory University in Atlanta, Georgia, where he focused on the pharmacology and regulation of adrenergic receptors. His post-doctoral fellowship at the National Institutes of Health related to the pharmacology and regulation of dopamine receptor subtypes.